Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0.89
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University,...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Data is available to registered users only
Buy
Sell